Newer Oral Anticoagulants Beneficial for Atrial Fibrillation

Share on FacebookTweet about this on TwitterShare on LinkedIn

In patients with atrial fibrillation (AF), novel oral anticoagulants (NOACs) appear to provide greater overall clinical benefit when compared with vitamin K antagonists. A systematic review and meta-analysis found than NOACs were associated with lower rates of total mortality, cardiovascular mortality, stroke, and systemic embolism in patients with AF when compared with vitamin K antagonists.

Abstract: Circulation, November 13, 2012.

Submit a Comment

Your email address will not be published. Required fields are marked *

sixteen + fifteen =